GoodRx Holdings, Inc.

Annual Trend FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Net income (loss) $43.8m
$66.0m +50.82%
($293.6m) -544.56%
$25.3m +108.60%
($32.8m) -229.99%
($8.9m) +72.99%
$16.4m +284.82%
$30.4m +85.72%
Depreciation and amortization $9.8m $13.6m $18.4m $34.5m $54.2m $107.7m $69.5m $85.2m $88.6m
Amortization of debt issuance costs and discounts $1.2m $3.4m $3.4m $3.4m $3.4m $3.4m $2.5m $1.8m
Deferred income taxes ($2.4m) ($5.7m) ($10.9m) $12.9m ($497k) ($65.6m) ($11.9m) $20.1m $29.8m
Stock-based compensation expense $1.8m $3.7m $397.3m $160.5m $120.2m $104.8m $99.0m $76.6m $69.1m
Stock-based compensation included in capitalized software $385k $2.4m $7.7m $9.0m $13.1m $16.1m $15.1m $69.1m
Accounts receivable ($12.8m) ($14.5m) ($16.1m) ($43.9m) $1.4m ($26.5m) ($2.3m) ($88.0m) $8.7m
Accounts payable $665k $515k $2.2m $4.2m ($874k) $17.5m ($21.2m) $4.1m ($9.3m)
Capitalized software included in accounts payable and accrued expenses and other current liabilities $1.3m $1.1m $4.2m $7.8m $8.1m $7.7m
Accrued expenses and other current liabilities $77k $11.2m $15.0m $14.0m ($5.3m) $21.3m $25.7m $1.2m
Other $0 $0 $1.3m $0 ($2.5m)
Prepaid expenses and other assets ($2.6m) $102k ($40.9m) ($17.1m) ($13.6m) ($32.2m) $6.3m ($8.4m)
Other liabilities $3.0m $168k $2.9m ($711k) $2.1m $914k ($1.4m) $2.0m
Net cash provided by operating activities $45.3m
$83.3m +84.05%
$131.3m +57.70%
$178.8m +36.12%
$146.8m -17.90%
$138.3m -5.78%
$183.9m +32.97%
$167.9m -8.69%
$201.6m +20.06%
Purchase of property and equipment ($804k) ($1.4m) ($20.6m) ($4.6m) ($4.0m) ($1.0m) ($1.2m) ($3.5m) ($69.9m)
Acquisitions ($31.3m) ($55.8m) ($140.3m) ($156.9m) $0 $0 ($43.4m) ($13.4m)
Net cash used in investing activities ($3.5m) ($37.1m) ($91.6m) ($178.7m) ($210.5m) ($55.8m) ($70.3m) ($120.0m) ($85.8m)
Loss on extinguishment of debt $2.9m $4.9m $0 $0 $0 $0 $2.1m $0
Proceeds from long-term debt $901.8m $154.6m $28.0m $0 $0 $0 $472.0m $0
Payments on long-term debt ($294.9m) ($211.8m) ($35.0m) ($7.0m) ($7.0m) ($5.3m) ($639.0m) ($5.0m)
Payments of debt issuance costs ($25.6m) ($2.2m) ($1.3m) $0 $0 $0 ($2.7m) $0
Repurchases of Class A common stock $0 $0 ($101.7m) ($104.0m) ($158.8m) ($216.4m)
Employee taxes paid related to net share settlement of equity awards $0 ($78.7m) ($57.7m) ($20.6m) ($65.5m) ($29.8m) ($14.5m)
Net cash used in financing activities ($24.7m)
($54.8m) -121.48%
$905.8m +1753.52%
($30.5m) -103.37%
($120.2m) -293.82%
($167.4m) -39.23%
($337.5m) -101.62%
($234.5m) +30.53%
($101.0m) +56.94%
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Non-cash operating lease expense $45.3m $2.1m $4.5m $3.1m $3.3m $4.1m $4.2m $4.0m $201.6m
Loss on operating lease assets $0 $961k $1.4m $12.6m $1.4m $0 $4.4m
Loss on disposal of capitalized software $0 $0 $8.0m $0 $0
Loss on minority equity interest investment $0 $0 $4.0m $0 $0
Prescription reimbursement assets ($15.5m) ($7.5m) ($75.4m)
Prescription reimbursement liabilities $5.4m $10.4m $114.3m
Operating lease liabilities ($2.3m) $4.6m ($2.4m) ($4.0m) ($2.9m) ($5.0m) ($6.3m)
Capitalized software ($2.7m) ($4.3m) ($15.3m) ($29.9m) ($51.2m) ($54.7m) ($69.1m) ($70.5m)
Proceeds from exercise of stock options $3.3m $3.0m $5.3m $35.0m $9.2m $5.9m $19.0m $61k
Proceeds from employee stock purchase plan $0 $0 $1.4m $1.8m $1.3m
Net change in cash and cash equivalents $17.1m ($8.6m) $945.5m $30.5m ($183.9m) ($84.9m) ($223.9m) ($186.5m)
Cash and cash equivalents
Beginning of period $34.6m $26.1m $971.6m $941.1m $757.2m $672.3m $448.3m $261.8m
Income taxes paid, net of refunds received $0 ($78.7m) ($18.1m) $4.4m $17.2m $23.6m $13.1m
Interest paid $18.7m $48.4m $24.5m $20.2m $30.7m $48.8m $55.1m $40.8m $40.8m
Right-of-use assets obtained in exchange for operating lease liabilities $29.5m $234k $2.9m $22.5m $52k $2.0m $9.2m
Capitalized software transferred from prepaid assets $0 $0 $5.8m $0 $0